Guillain-Barre Syndrome (GBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Guillain-Barre Syndrome (GBS) Market Outlook

Thelansis’s “Guillain-Barre Syndrome (GBS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Guillain-Barre Syndrome (GBS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Guillain-Barre Syndrome (GBS) Overview

Guillain-Barre Syndrome (GBS) is a type of acute paralytic neuropathy that is both common and severe. Typically involves progressive limb weakness accompanied by decreased or absent reflexes. However, some patients experience localized weakness or other symptoms, such as facial diplegia or paraesthesia. GBS is also associated with several other disorders, such as Miller-Fisher syndrome and Bickerstaff brainstem encephalitis. These conditions can share similar biomarkers but present with different clinical features. GBS can be broadly classified into two types: acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), based on the site of the target antigen. The underlying mechanisms of GBS involve both innate and adaptive immunity. Innate immunity is associated with dendritic cells, complement fractions, mast cells, and specific toll-like receptors. Adaptive immunity is characterized by IL17 and IL22 secretion, anomalies in CD4(+)CD25(+) regulator T-cells, and anti-ganglioside and anti-nodes of Ranvier protein IgG. GBS is triggered by various factors, including infections by viruses such as dengue, hepatitis E, and Zika, as well as cross-reactivity phenomena in cases of Campylobacter jejuni diarrhea. Factors that affect prognosis include older age, rapid disease progression, diarrhea as a triggering factor, and the need for mechanical ventilation. Clinical scores such as EGRIS can be used to assess the short-term risk of intubation, and the EGOS and mEGOS can be used to determine the capacity to walk at six months or four weeks, respectively.

• Estimate incidence rates of Guillain-Barre Syndrome in Europe and North America showed a similar range of 1 to 2 cases per 100000 population per year.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: